138 related articles for article (PubMed ID: 14655481)
1. [Prospective treatment study of irbesartan. Diabetic kidneys regain function].
Lehnert H; Bramlage P; Pittrow D; Kirch W
MMW Fortschr Med; 2003 Oct; 145(41):41. PubMed ID: 14655481
[No Abstract] [Full Text] [Related]
2. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.
Kaiser T; Florack C; Sawicki PT
Diabetes Care; 2004 Jun; 27(6):1521; author reply 1521-2. PubMed ID: 15161820
[No Abstract] [Full Text] [Related]
3. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422
[No Abstract] [Full Text] [Related]
4. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Lehnert H; Bramlage P; Pittrow D; Kirch W
MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
[TBL] [Abstract][Full Text] [Related]
5. EC approves irbesartan for the treatment of diabetic renal disease.
Cardiovasc J S Afr; 2002; 13(4):216-7. PubMed ID: 12402931
[No Abstract] [Full Text] [Related]
6. Angiotensin II receptor blockers and nephropathy trials.
Bloomgarden ZT
Diabetes Care; 2001 Oct; 24(10):1834-8. PubMed ID: 11574450
[No Abstract] [Full Text] [Related]
7. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Palmer AJ; Roze S; Valentine WJ; Ray JA; Frei A; Burnier M; Hess B; Spinas GA; Brändle M
Swiss Med Wkly; 2006 May; 136(21-22):346-52. PubMed ID: 16779715
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191
[No Abstract] [Full Text] [Related]
9. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
10. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
Schmieder RE; Krekler M
MMW Fortschr Med; 2005 Aug; 147(31-32):43. PubMed ID: 16128197
[No Abstract] [Full Text] [Related]
11. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Frei A; Palmer AJ; Burnier M; Hess B
Praxis (Bern 1994); 2006 Mar; 95(11):401-8. PubMed ID: 16570646
[TBL] [Abstract][Full Text] [Related]
12. [Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure].
MMW Fortschr Med; 2003 Apr; 145(17):55. PubMed ID: 12808810
[No Abstract] [Full Text] [Related]
13. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
Schmieder RE; Krekler M
MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
[TBL] [Abstract][Full Text] [Related]
14. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
Tschöpe C; Tschöpe R; Unger T
MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162
[No Abstract] [Full Text] [Related]
15. Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
Ann Intern Med; 2003 Apr; 138(7):I43. PubMed ID: 12667050
[No Abstract] [Full Text] [Related]
16. Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.
Cetinkalp SS; Karadeniz MM; Erdogan MA; Ozgen GA; Yilmaz CO
Saudi Med J; 2008 Oct; 29(10):1414-8. PubMed ID: 18946564
[TBL] [Abstract][Full Text] [Related]
17. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
18. What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?
Ruggenenti P; Remuzzi G
Nat Clin Pract Nephrol; 2006 May; 2(5):250-1. PubMed ID: 16932436
[No Abstract] [Full Text] [Related]
19. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
[TBL] [Abstract][Full Text] [Related]
20. Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Doggrell SA
Expert Opin Pharmacother; 2002 May; 3(5):625-8. PubMed ID: 11996640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
